Aricept

Type: Product
Name: Aricept
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

Investigational therapy focuses on slowing progression in mild to moderate Alzheimer's -- ScienceDaily

Patients with mild to moderate Alzheimer's disease currently have no treatment options to slow brain cell deterioration. Researchers at Houston Methodist's Nantz National Alzheimer Center are studying an investigational drug that proposes to do just ... [Published DailyMe.Com - Aug 21 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

Investigational Therapy Focuses on Slowing Progression in Mild to Moderate Alzheimer's

’s Nantz National Alzheimer Center only Texas site to offer this study Contact InformationAvailable for logged-in reporters onlyNewswise — Patients with mild to moderate Alzheimer’s disease currently have no treatment options to slow brain cell deterioration. ... [Published Newswise - Aug 20 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 1 reports

Struggling Eisai files its thyroid cancer drug lenvatinib in U.S., EU

Still suffering from the loss of patent protection on its big Alzheimer's drug Aricept, Japan's Eisai today said that the company had fired off a pair of applications for its new cancer drug to U.S. as well as European regulators.Eisai is seeking to gain ... [Published FierceBiotech - Aug 18 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

Anger as four surgeries refuse to give out Alzheimer's drug

A HUSBAND has spoken out over four surgeries in the town refusing to prescribe a drug which can temporarily improve or stabilise the symptoms of Alzheimer's disease.The Warrington Guardian reported in 2011 many relatives of Alzheimer’s patients had expressed ... [Published Congleton Guardian - Aug 14 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

Health Column: Treating Alzheimer’s dementia with medications

A radiant, smiling grandpa is frolicking with his grandchildren on a sunny, wildflower-covered hillside. In the television version, serene violin music wafts in the background. This is the unrealistic gist of the ads for the two most commonly prescribed ... [Published Glenwood Independent - Aug 11 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

My dad; death, dementia and ducklings

It was pneumonia that finally did for my demented Dad. They call it the 'old peoples' friend' - I'm not sure why, it didn't seem very friendly to me. But the morphine helped.They say about dementia that you die with it, not from it. And that was true ... [Published Herald Scotland - Aug 11 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

GliaCure Raises $5.8M Series B, Plans Initial Clinical Trial of Alzheimer's Drug

(c) 2014 Dow Jones & Company, Inc.GliaCure Inc. has raised $5.8 million to launch clinical studies for a novel Alzheimer's disease drug, one of several new therapeutics startups are advancing against a condition that has frustrated drug makers.Alzheimer's ... [Published Dow Jones Financial Information Services - Aug 04 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

Alzheimer's Disease Stole My Grandmother

As the matriarch of our family, my grandmother guided my and my relatives life as far back as I can remember. She would go to work, make dinner, plan reunions and still make scarves for us for the winter all in one day! A FystyMama before I coined the ... [Published Chicago Now - Jul 31 2014]
First reported Jul 30 2014 - Updated Jul 31 2014 - 1 reports

Pfizer hit by Viagra patent expiration

The expiration of US pharmaceutical company Pfizer’s patent for Viagra in many European countries was a contributing factor to the drop in revenue that it reported yesterday (July 29) when releasing its second-quarter earnings data.The company’s revenue ... [Published World Intellectual Property Review - Jul 30 2014]
Entities: Viagra, Pfizer Inc, Patent
First reported Jul 29 2014 - Updated Jul 30 2014 - 2 reports

Pfizer Beats on Q2 Earnings, Revs Despite Generic Pressures

Pfizer Inc. ( PFE - Analyst Report ) posted second quarter 2014 earnings of 58 cents per share, a couple of cents above the Zacks Consensus Estimate and 4% above the year-ago earnings. Revenues, which declined 2% to $12.8 billion, were above the Zacks ... [Published Zacks.com - Jul 29 2014]
First reported Jul 14 2014 - Updated Jul 15 2014 - 5 reports

Alzheimer’s Drug Fails Mid-Stage Study

News Categories TC-1734 not superior to donepezil, researchers findDisappointing results have been reported from a phase IIb monotherapy clinical trial of TC-1734 (Targacept, Inc.) as a treatment for mild-to-moderate Alzheimer’s disease (AD). The investigational ... [Published P&T Community - Jul 15 2014]
First reported Jun 13 2014 - Updated Jun 13 2014 - 1 reports

newbie

Hello,I'm new to the boards. My mom has dementia and has been on aricept and namenda for over 8 years. She has been sundowning for the past year, getting very agitated and talking to people who have been dead over fifty years. She stays with me at ... [Published HealthBoards - Jun 13 2014]
Entities: Aricept

Quotes

...strategies and are pleased with the progress toto date," said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. "With our Phase 2a Alzheimer's trial on track to commence in 2014 and data from the first part of the trial expected to be reported in mid-2015, we remain enthusiastic about our prospects. Clearly we continue to execute on our growth strategy as we enter the clinic with ANAVEX 2-73 and ANAVEX PLUS and conduct additional preclinical work with other pipeline products."
So now it's over. It wasn't the six months (eight months tops) that I predicted I would spend in Glasgow; it was two years. "The better the care, the longer the patient will live" the doctor said; so I blame myself
"I started waiting in her driveway for her to come out when I took her to the doctor so she couldn't accuse me of stealing things" said Wardwell
...management team and I am very pleased to welcome him to Anavex," said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. "Dr. Zografidis has extensive pharmaceutical industry experience in clinical operations and project management across a variety of therapeutic areas. One of his most valuable strengths is the knowledge of applying population pharmacokinetics to analyze variability in drug concentrations between patients and hence provide additional safety details often requested by regulatory authorities. In addition, Dr. Zografidis has considerable knowledge in regulatory compliance and working with clinical contract research organizations (CROs) to improve overall business practices." Dr. Zografidis has more than 25 years of experience in the pharmaceutical and healthcare industry, including 12 years at Wyeth (now Pfizer) in clinical...

More Content

All (45) | News (40) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Huperzine: Advanced Herbal Support for Memory a... [Published Nutrition Review - Aug 21 2014]
Investigational therapy focuses on slowing prog... [Published DailyMe.Com - Aug 21 2014]
Investigational Therapy Focuses on Slowing Prog... [Published Newswise - Aug 20 2014]
Struggling Eisai files its thyroid cancer drug ... [Published FierceBiotech - Aug 18 2014]
Eisai files for US and EU approval of lenvatini... [Published Pharma Letter - Aug 18 2014]
Anger as four surgeries refuse to give out Alzh... [Published Congleton Guardian - Aug 14 2014]
Q&A session with Warrington's top doc [Published Warrington Guardian - Aug 13 2014]
Anavex Reports Fiscal Third Quarter 2014 Financ... [Published Good Day Sacramento - Aug 13 2014]
Health Column: Treating Alzheimer’s dementia wi... [Published Glenwood Independent - Aug 11 2014]
My dad; death, dementia and ducklings [Published Herald Scotland - Aug 11 2014]
Webber's friends question her end-of-life compe... [Published Seacoast Online - Aug 10 2014]
Anavex Appoints Experienced Pharma Executive as... [Published Scottrade - Aug 07 2014]
Neuren Pharmaceuticals : Patent Issued for Cycl... [Published 4 Traders - Aug 07 2014]
Drugs That Work Against Each Other [Published Bottom Line Publications - Aug 07 2014]
GliaCure Raises $5.8M Series B, Plans Initial C... [Published Dow Jones Financial Information Services - Aug 04 2014]
AMBS: Why I'm Still Optimistic On LymPro and Am... [Published Yahoo! Finance - Aug 04 2014]
Alzheimer's Disease Stole My Grandmother [Published Chicago Now - Jul 31 2014]
Sugar harms your brain health and drives the Al... [Published Sott.net - Jul 31 2014]
Dementia diagnoses on the rise [Published Pharmafocus - Jul 30 2014]
Pfizer hit by Viagra patent expiration [Published World Intellectual Property Review - Jul 30 2014]
Dr Reddy's Q1 net may rise 42% at Rs 513 cr: P ... [Published Moneycontrol.com - Jul 30 2014]
To Solve Alzheimer’s Mystery, Better Biological... [Published Xconomy - Jul 29 2014]
Pfizer Beats on Q2 Earnings, Revs Despite Gener... [Published Zacks.com - Jul 29 2014]
Pfizer Beats Forecasts Despite Slumping Sales [Published RTTNews.com - Jul 29 2014]
Eisai:R&I Affirms AA-/a-1+,Changes Outlook to N... [Published Noodls - Jul 28 2014]
How Sugar Harms Your Brain Health and Drives Al... [Published Mercola - Jul 24 2014]
Anavex Life Sciences : Achieves Key Milestone a... [Published 4 Traders - Jul 21 2014]
"Non-Mucoadhesive Film Dosage Forms" in Patent ... [Published Pharmacy Choice - Jul 18 2014]
Arthritis drug could also halt Alzheimer's: Tre... [Published Mail Online UK - Jul 16 2014]
Ted Rall: Moths to Flame [Published River Cities Reader - Jul 16 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
newbie [Published HealthBoards - Jun 13 2014]
Hello,I'm new to the boards. My mom has dementia and has been on aricept and namenda for over 8 years. She has been sundowning for the past year, getting very agitated and talking to people who have been dead over fifty years. She stays with me at ...
A Look at Pfizer’s Recent Financial Performance [Published Wall St. Cheat Sheet - May 15 2014]
Pfizer ( NYSE:PFE ) is getting a lot of attention lately, mostly given its potential deal with AstraZeneca ( NYSE:AZN ). This topic has been thoroughly covered lately. But despite the drama surrounding the headlines of late, Pfizer is still my ...
Chase Pharmaceuticals Corporation inks $21 mln ... [Published PE Hub Blog - May 12 2014]
Chase Pharmaceuticals Corporation has raised a $21 million Series B financing led by New Rhein Healthcare Investors . Other new investors include Edmond de Rothschild Investment Partners and Cipla Ventures , the new venture capital arm of Cipla ...
Hello, new here [Published HealthBoards - Mar 01 2014]
Hello,My name is Lisa and I have been my mom's caregiver since December. I had been trying to get her (now "ex") husband to get her diagnosed for over 2 years and nothing was done, so as soon as I got her here, I took her to a GP and immediately had a ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.